Purpose of this Study
For this type of cancer, standard treatment includes radiation therapy along with chemotherapy medicines such as carboplatin and paclitaxel. In this study, people will also receive extra chemotherapy for up to six months after the standard treatment is finished. This extra treatment is called consolidation chemotherapy. It uses common cancer medicines such as fluorouracil, leucovorin, oxaliplatin, and docetaxel. Some people may also receive a medicine called durvalumab, which helps the immune system fight cancer.
Who Can Participate?
Eligibility
This study is for adults who have a newly diagnosed cancer in the food pipe or where the food pipe meets the stomach. The cancer must be confirmed by lab testing and be at a certain stage that has not spread too far. People in the study will need to receive treatment with both radiation and chemotherapy. They must also have kidneys, liver, and blood that are working well enough to safely take part in the study.
Age Range
18-110
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
Description
The purpose of this study is to determine if adding additional chemotherapy, called consolidation chemotherapy, to the standard treatment can improve the tumor response.
Locations
Duke University Hospital
Visit Timing
Weekdays
Compensation
No
Spanish Materials Available
Yes
Study Details
Full Title
A single-arm study of upfront chemotherapy with radiation therapy (CRT) followed by chemotherapy in localized esophageal adenocarcinoma
Principal Investigator
Manisha
Palta
Protocol Number
PRO00120182
NCT ID
NCT07603375
Phase
N/A
Enrollment Status
Pending Open to Enrollment